Market Research Logo

Malaria - Pipeline Review, H1 2018

Malaria - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H1 2018, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 11, 10, 56, 22 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 12, 47 and 34 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Malaria - Overview
Malaria - Therapeutics Development
Malaria - Therapeutics Assessment
Malaria - Companies Involved in Therapeutics Development
Malaria - Drug Profiles
Malaria - Dormant Projects
Malaria - Discontinued Products
Malaria - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Malaria, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Malaria - Pipeline by 4SC AG, H1 2018
Malaria - Pipeline by AbbVie Inc, H1 2018
Malaria - Pipeline by Agilvax Inc, H1 2018
Malaria - Pipeline by Akshaya Bio Inc, H1 2018
Malaria - Pipeline by AlfaSigma SpA, H1 2018
Malaria - Pipeline by Allergy Therapeutics Plc, H1 2018
Malaria - Pipeline by Altimmune Inc, H1 2018
Malaria - Pipeline by Artificial Cell Technologies Inc, H1 2018
Malaria - Pipeline by AstraZeneca Plc, H1 2018
Malaria - Pipeline by Bharat Biotech Ltd, H1 2018
Malaria - Pipeline by Cadila Healthcare Ltd, H1 2018
Malaria - Pipeline by Carna Biosciences Inc, H1 2018
Malaria - Pipeline by CEL-SCI Corp, H1 2018
Malaria - Pipeline by Celgene Corp, H1 2018
Malaria - Pipeline by Cilian AG, H1 2018
Malaria - Pipeline by Curevac AG, H1 2018
Malaria - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Malaria - Pipeline by DesignMedix Inc, H1 2018
Malaria - Pipeline by DMG Deutsche Malaria GmbH, H1 2018
Malaria - Pipeline by Eisai Co Ltd, H1 2018
Malaria - Pipeline by Fosun International Ltd, H1 2018
Malaria - Pipeline by GenVec Inc, H1 2018
Malaria - Pipeline by Genzyme Corp, H1 2018
Malaria - Pipeline by GeoVax Labs Inc, H1 2018
Malaria - Pipeline by GlaxoSmithKline Plc, H1 2018
Malaria - Pipeline by Hager Biosciences LLC, H1 2018
Malaria - Pipeline by iBio Inc, H1 2018
Malaria - Pipeline by Ichor Medical Systems Inc, H1 2018
Malaria - Pipeline by ID Pharma Co Ltd, H1 2018
Malaria - Pipeline by Immunovaccine Inc, H1 2018
Malaria - Pipeline by IPCA Laboratories Ltd, H1 2018
Malaria - Pipeline by Kancera AB, H1 2018
Malaria - Pipeline by Kymab Ltd, H1 2018
Malaria - Pipeline by Lipocure Ltd, H1 2018
Malaria - Pipeline by LondonPharma Ltd, H1 2018
Malaria - Pipeline by Marinomed Biotech AG, H1 2018
Malaria - Pipeline by Merck KGaA, H1 2018
Malaria - Pipeline by Microbiotix Inc, H1 2018
Malaria - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Malaria - Pipeline by Mymetics Corp, H1 2018
Malaria - Pipeline by Nobelpharma Co Ltd, H1 2018
Malaria - Pipeline by Novartis AG, H1 2018
Malaria - Pipeline by Osivax SAS, H1 2018
Malaria - Pipeline by Otsuka Holdings Co Ltd, H1 2018
Malaria - Pipeline by PaxVax Inc, H1 2018
Malaria - Pipeline by Pfizer Inc, H1 2018
Malaria - Pipeline by Protein Potential LLC, H1 2018
Malaria - Pipeline by Rodos BioTarget GmbH, H1 2018
Malaria - Pipeline by Sanaria Inc, H1 2018
Malaria - Pipeline by Sanofi, H1 2018
Malaria - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2018
Malaria - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Malaria - Pipeline by Theravectys SA, H1 2018
Malaria - Pipeline by Titan Pharmaceuticals Inc, H1 2018
Malaria - Pipeline by VLP Biotech Inc, H1 2018
Malaria - Pipeline by VLP Therapeutics LLC, H1 2018
Malaria - Dormant Projects, H1 2018
Malaria - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Malaria, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report